NCT03337724: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT03337724
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, AKT, PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2|Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have PIK3CA/AKT1/PTEN-altered status in tumor tissue by next-generation sequencing (NGS)
Exclusions: History of or known presence of brain or spinal cord metastases
https://ClinicalTrials.gov/show/NCT03337724

Comments are closed.

Up ↑